Characteristic | BRCA1 mutation (n = 11) | BRCA2 mutation (n = 43) | BRCA1 and BRCA2 mutation (n = 36) | P Valueb |
Age≥65y | 0.040 | |||
No | 3 (30.0) | 26 (60.5) | 26 (74.3) | |
Yes | 7 (70.0) | 17 (39.5) | 9 (25.7) | |
BMI≥28 kg/m2 | 0.025 | |||
No | 1 (11.1) | 15 (35.7) | 19 (57.6) | |
Yes | 8 (88.9) | 27 (64.3) | 14 (42.4) | |
Diabetes history | 0.911 | |||
No | 5 (71.4) | 24 (77.4) | 21 (80.8) | |
Yes | 2 (28.6) | 7 (22.6) | 5 (19.2) | |
Hypertension history | 0.162 | |||
No | 2 (25.0) | 16 (47.1) | 19 (61.3) | |
Yes | 6 (75.0) | 18 (52.9) | 12 (38.7) | |
AJCC stage | 0.087 | |||
Early (stage I-II) | 8 (72.7) | 38 (88.4) | 25 (69.4) | |
Advanced (stage III-IV) | 3 (27.3) | 5 (11.6) | 11 (30.6) | |
Grade | <0.001 | |||
Low (G1 - 2) | 3 (27.3) | 26 (60.5) | 7 (19.4) | |
High (G3) | 8 (72.7) | 17 (39.5) | 29 (80.6) | |
Histology | 0.181 | |||
Endometrioid type | 8 (72.7) | 40 (93.0) | 32 (88.9) | |
Non-endometrioid type | 3 (27.3) | 3 (7.0) | 4 (11.1) | |
Lymph node metastasis | 0.017 | |||
No | 7 (77.8) | 38 (97.4) | 24 (77.4) | |
Yes | 2 (22.2) | 1 (2.6) | 7 (22.6) | |
Depth of myometrial invasion | 0.462 | |||
<50% | 3 (42.9) | 25 (62.5) | 16 (50.0) | |
≥50% | 4 (57.1) | 15 (37.5) | 16 (50.0) | |
Peritoneal cytology | 0.713 | |||
Negative | 7 (100.0) | 31 (96.9) | 27 (93.1) | |
Positive | 0 | 1 (3.1) | 2 (6.9) | |
Residual disease | 0.024 | |||
No | 4 (57.1) | 26 (76.5) | 30 (93.8) | |
Yes | 3 (42.9) | 8 (23.5) | 2 (6.3) | |
Radiation therapy use | 0.904 | |||
No | 5 (55.6) | 25 (59.5) | 19 (52.8) | |
Yes | 4 (44.4) | 17 (40.5) | 17 (47.2) | |
Chemotherapy use | 0.731 | |||
No | 3 (60.0) | 14 (66.7) | 15 (75.0) | |
Yes | 2 (40.0) | 7 (33.3) | 5 (25.0) | |
Molecular targeted therapy use | 0.256 | |||
No | 4 (80.0) | 27 (81.8) | 17 (63.0) | |
Yes | 1 (20.0) | 6 (18.2) | 10 (37.0) |